Idera Pharmaceuticals Inc (IDRA)

[kld2]

I say it runs. Too much momentum building. In different times, before the merger, I believe traders and retail investors would drop it, retail concerned about dilution, traders toying with the huge float, etc., etc. This time it is different. If the ASCO data is confirmed (we will get data on 24 pts; 15 were in the abstract), the merger will go through; and if the merger goes through, IDRA will neither have a huge float or dwindling cash. I can almost feel it, I've been around this stock so long. I say we see 2.50 over the next two weeks; not saying it will stay there; just saying it will touch there, esp. if the data is good on June 4 and the investor show that follows. No other biotech--not NKTR, not DVAX, not Checkmate--have the data IDRA has on refractory patients. It has fast-track designation as well. Things are going to get interesting as they reach full enrollment toward the end of the year. They're looking at 60 patients; right now they might have 30-35. With seven sites up and running, each site needs to enroll two per month for two months and they have it. Needless to say, I am optimistic. I've loaded; I await.